Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE.

J Clin Oncol. 2010 Jan 1;28(1):149-53. doi: 10.1200/JCO.2009.24.1455. Epub 2009 Nov 16.

2.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD.

Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Review.

PMID:
25792179
3.

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.

PMID:
18840366
4.

Epothilones in the treatment of ovarian cancer.

Diaz-Padilla I, Oza AM.

Future Oncol. 2011 Apr;7(4):559-68. doi: 10.2217/fon.11.26. Review.

PMID:
21463144
5.

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.

Rivera E, Lee J, Davies A.

Oncologist. 2008 Dec;13(12):1207-23. doi: 10.1634/theoncologist.2008-0143. Epub 2008 Dec 16. Review.

6.

Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.

Yardley DA.

Clin Breast Cancer. 2008 Dec;8(6):487-92. doi: 10.3816/CBC.2008.n.058. Review.

PMID:
19073502
7.

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.

Dumontet C, Jordan MA, Lee FF.

Mol Cancer Ther. 2009 Jan;8(1):17-25. doi: 10.1158/1535-7163.MCT-08-0986. Review.

8.

Ixabepilone: a new microtubule-targeting agent for breast cancer.

Higa GM, Abraham J.

Expert Rev Anticancer Ther. 2008 May;8(5):671-81. doi: 10.1586/14737140.8.5.671. Review.

PMID:
18471040
9.

Preclinical discovery of ixabepilone, a highly active antineoplastic agent.

Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.

Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Review.

PMID:
18347795
10.

Clinical experience with epothilones in patients with breast cancer.

Buzdar AU.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S71-8. Review.

PMID:
18637402
11.

Profile and potential of ixabepilone in the treatment of pancreatic cancer.

Smaglo BG, Pishvaian MJ.

Drug Des Devel Ther. 2014 Jul 14;8:923-30. doi: 10.2147/DDDT.S52964. eCollection 2014. Review.

12.

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

Lee JJ, Swain SM.

Semin Oncol. 2005 Dec;32(6 Suppl 7):S22-6. Review.

PMID:
16360719
13.

Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.

Andreopoulou E, Muggia F.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S54-60. Review.

PMID:
18637400
14.

Therapeutic potential of patupilone in epithelial ovarian cancer and future directions.

Rogalska A, Marczak A.

Life Sci. 2018 Jul 15;205:38-44. doi: 10.1016/j.lfs.2018.04.058. Epub 2018 May 1. Review.

PMID:
29727613
15.

Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer.

Rose PG.

Semin Oncol Nurs. 2003 Nov;19(4 Suppl 2):25-35. Review.

PMID:
14702918

Supplemental Content

Support Center